More tools

Immix Biopharma, Inc.

IMMX

Immix Biopharma, Inc.

1.61

-0.07

(-4.17%)

Today

As of 3:37 PM Eastern

Options AI - All Directions

Apr 17 Expected Move

See where the options market thinks IMMX will move from here.

2025-03-03 09:00:002025-03-13 12:30:002025-03-25 16:00:002025-04-07 11:30:002025-04-17 15:00:00$6.21-$2.99

Immix Biopharma, Inc.

Market Cap: 44.63 million

PE Ratio: -2.12

Volume: 45.42 thousand

Sector: Healthcare

Industry: Biotechnology

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.